Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9808674 | 1.00 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL504257 | 1.00 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL504255 | 1.00 | TRPV1 (0.70) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL1586047 | 0.98 | TRPV1 (0.67) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL1585893 | 0.93 | TRPV1 (0.61) | TRPV1MAPTHPGDMEN1TP53 | |
| SCHEMBL29530847 | 0.93 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28755565 | 0.93 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9808706 | 0.93 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL258429 | 0.93 | TRPV1 (0.74) | TRPV1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL155980 | 0.87 | TRPV1 (0.85) | TRPV1MAPTHPGDMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11904047-B1 | Formulation and delivery systems for herbal compositions for the treatment of canker sores (recurrent aphthous stomatitis) and related conditions | TRAN SANDIE (US) | 2024-02-20 | — | — | US | claimed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260060989-A1 | Charged Ion Channel Blockers And Methods For Use | NOCION THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4680210-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS Lohmann Therapie-Systeme AG (DE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250263386-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250263374-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250205183-A1 | METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS | CLIFF CARTWRIGHT CORP (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4054559-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | disclosed |
| US-20220274936-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2022-09-01 | — | — | US | disclosed |
| CN-114828845-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11332446-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220098143-A1 | CAPSAICIN AND TRPV1 MODULATOR COMBINATIONS AND METHODS OF USE THEREOF | PANO THERAPEUTICS INC (US) | 2022-03-31 | — | — | US | disclosed |
| US-11253493-B2 | Compositions and methods affecting exercise performance | CLIFF-CARTWRIGHT CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263386-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885MAPT 2578/4885HPGD 1583/4885 |
| US-11253493-B2 | Compositions and methods affecting exercise performance | ASIC1, TRPC3, TRPC7 | TRPV1 4/4885MAPT 3509/4885HPGD 1944/4885 |
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPA1 | TRPV1 1/4885MAPT 1166/4885HPGD 2579/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885MAPT 1799/4885HPGD 1754/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885MAPT 1799/4885HPGD 1754/4885 |
| US-20250205183-A1 | METHODS OF TREATING MUSCLE CRAMPING AND RELATED COMPOSITIONS | PYGM, TNNC1, RYR1 | TRPV1 10/4885MAPT 3328/4885HPGD 713/4885 |
| US-11904047-B1 | Formulation and delivery systems for herbal compositions for the treatment of canker sores (recurrent aphthous stomatitis) and related conditions | TAS2R46, IL6, TAS2R8 | TRPV1 364/4885MAPT 1224/4885HPGD 1165/4885 |
| US-11332446-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885MAPT 2578/4885HPGD 1583/4885 |
| US-20260060989-A1 | Charged Ion Channel Blockers And Methods For Use | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MAPT 1178/4885HPGD 3470/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | TRPV1 2/4885MAPT 3147/4885HPGD 2311/4885 |
| US-20220098143-A1 | CAPSAICIN AND TRPV1 MODULATOR COMBINATIONS AND METHODS OF USE THEREOF | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885MAPT 2782/4885HPGD 596/4885 |
| US-20250263374-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885MAPT 1799/4885HPGD 1754/4885 |
| US-20220274936-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, ASIC1, TRPA1 | TRPV1 1/4885MAPT 1858/4885HPGD 1585/4885 |
| US-20250270189-A1 | Ester Substituted Ion Channel Blockers and Methods for Use | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MAPT 2258/4885HPGD 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.